Abbott Laboratories (ABT) fundamentals from SEC filings — revenue $44.3B, net margin 14.7%, diluted EPS $3.72 in FY2025. Revenue, margins, EPS and free cash flow, year by year.
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $43.1B | $43.7B | $40.1B | $42.0B | $44.3B |
| Net income | $7.1B | $6.9B | $5.7B | $13.4B | $6.5B |
| Net margin | 16.4% | 15.9% | 14.3% | 31.9% | 14.7% |
| Diluted EPS | $3.94 | $3.91 | $3.26 | $7.64 | $3.72 |
| Free cash flow | $8.6B | $7.8B | $5.1B | $6.4B | $7.4B |
Figures are as reported to the SEC (EDGAR companyfacts), in the filer's own fiscal years.
Sign in to PortfolioX for the full analysis — ten years of history, segment and geographic breakdowns, valuation multiples, analyst estimates and filings. · PortfolioX home